Land: Storbritannien
Sprog: engelsk
Kilde: VMD (Veterinary Medicines Directorate)
Enrofloxacin
Bayer plc
QJ01MA90
Enrofloxacin
Oral suspension
POM-V - Prescription Only Medicine – Veterinarian
Cats
Antimicrobial
Expired
2011-08-19
Revised: May 2016 AN: 00881/2015 Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Baytril flavour 25 mg/ml oral suspension for cat (all MS except DK, FI, IS, NO, SE and ES) (The product name will be translated into national languages) Baytril Sabor 25 mg/ml suspensión oral para gatos (ES) Lorenax vet. 25 mg/ml oral suspension for cat (DK), Baytril vet. 25 mg/ml oral suspension for cat (FI, IS, NO and SE) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the product contains: ACTIVE SUBSTANCE: Enrofloxacin 25 mg EXCIPIENTS: Ascorbic acid (E300) 0.2 mg Sorbic acid (E200) 2 mg For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Oral suspension White to yellow-white suspension 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cat 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of single or mixed bacterial infections of the respiratory, alimentary and urinary tract, skin or wounds caused by the following enrofloxacin-sensitive Gram-negative and Gram-positive bacteria: Staphylococci,_ E. coli, Haemophilus _spp._ _and_ Pasteurella _spp_._ Revised: May 2016 AN: 00881/2015 Page 2 of 7 4.3 CONTRAINDICATIONS Do not use in Animals with existing impairment of cartilage growth Animals with a known history of seizures_, _ since enrofloxacin may cause CNS stimulation. Animals with known hypersensitivity to fluoroquinolones or any of the excipients For use in pregnant animals see section 4.7 and for interactions with other medicinal products see section 4.8 4.4 SPECIAL WARNINGS Do not use in cases of known resistance to quinolones because of near-total cross- resistance with these compounds and complete cross-resistance with other fluoroquinolones. In animals where product administration is associated with excessive salivation or where difficulty administering the required dose is experienced, administration should be discontinued and an alternative therapy used. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Læs hele dokumentet